| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.06 | 0.3 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.085 | 0.3 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.3 |